Job title: Vice President, Biomarkers & Translational Research
Mitch Raponi, PhD, is Vice President of Biomarker Development & Translational Research at BeiGene. He is responsible for designing and executing companion diagnostic strategies to support the development and commercialization of the companies immune-oncology and targeted cancer therapeutic pipeline. Mitch was previously VP of Molecular Diagnostics at Clovis Oncology where his work led to the development and approval of the first NGS-based companion diagnostics for the PARP inhibitor, rucaparib. Prior to this Mitch spent 15 years at Johnson & Johnson building biomarker and companion diagnostic programs within the diagnostics and pharmaceutical franchises. He received his PhD in Molecular Genetics and Biochemistry from the University of New South Wales, Australia, and has published in the fields of gene therapy, cancer genomics, and personalized medicine.
Panel Discussion: Patient Stratification & Biomarker Strategy 10:10 am
day: Day Two
On the Cutting-Edge of PARPi 9:30 am
day: Day One